| Jeffrey Cummings | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Nevada, Las Vegas |
| Country | USA |
| H-index | 190 |
| ORCID | 0000-0001-6396-9390 |
| Research Focus | Alzheimer's Disease, Lewy Body Dementia, Clinical Trials |
| Mechanisms | Cholinergic dysfunction, Drug development, Clinical outcome measures |
Jeffrey Cummings is a renowned neurologist and clinical researcher specializing in Alzheimer's disease and related dementias. He is a leading authority on clinical trials for neurodegenerative diseases and has been instrumental in developing new therapeutic approaches. As director of the Cleveland Clinic Lou Ruvo Center for Brain Health and later at UNLV, Dr. Cummings has led numerous clinical trials and contributed to the development of novel outcome measures for dementia research.
Dr. Cummings completed his medical training and neurology residency before specializing in behavioral neurology. He has held positions at UCLA, Georgetown University, and the Cleveland Clinic before joining UNLV. His work has focused on bridging the gap between basic science and clinical applications in neurodegeneration.
Dr. Cummings has been a principal investigator on numerous clinical trials:
He has developed and validated several clinical outcome measures:
Dr. Cummings has made significant contributions to understanding and treating Lewy body dementia:
Dr. Cummings has authored over 400 peer-reviewed publications and is a highly cited researcher in the field of neuroscience.
Dr. Cummings' contributions have fundamentally shaped modern Alzheimer's research:
His work continues to drive advances in understanding and treating these devastating diseases, with ongoing studies exploring novel therapeutic approaches and early intervention strategies. These efforts have significantly improved our ability to diagnose, monitor, and treat patients with neurodegenerative conditions.
Dr. Cummings maintains an active clinical practice focusing on patients with Alzheimer's disease and related disorders. He has developed comprehensive care approaches that combine pharmaceutical interventions with lifestyle modifications, emphasizing the importance of early diagnosis and individualized treatment plans.
His clinical experience has been instrumental in shaping clinical trial designs, ensuring that study outcomes are meaningful to patients and clinicians alike.